We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+16.1%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.69B
AUM Growth
+$3.31M
Cap. Flow
-$43.7M
Cap. Flow %
-2.58%
Top 10 Hldgs %
77.31%
Holding
52
New
6
Increased
5
Reduced
4
Closed
15
Avg Time Held Equity + Options
2 years
Top 10 Avg Time Held Equity + Options
1.3 years
Top 20 Avg Time Held Equity + Options
1.9 years
Avg Time Held Equity only
2.1 years
Top 10 Avg Time Held Equity only
1.3 years
Top 20 Avg Time Held Equity only
1.9 years

Top Buys

Rank Stock Value
1
ITOS icon
iTeos Therapeutics
ITOS
+$86.1M
2
ZYME icon
Zymeworks
ZYME
+$68M
3
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$23.6M
4
ALKS icon
Alkermes
ALKS
+$14.9M
5
VRNA
Verona Pharma
VRNA
+$14.8M

Top Sells

Rank Stock Value
1
PRTA icon
Prothena Corp
PRTA
+$143M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$82.5M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$12.1M
4
BEAM icon
Beam Therapeutics
BEAM
+$10.3M
5
DNA icon
Ginkgo Bioworks
DNA
+$8.34M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Miscellaneous 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PCRX icon
26
Pacira BioSciences
PCRX
$1.45B
$10.9M 0.65%
+457,471
New +$11.5M
2025 Q2
0 quarters
REPL icon
27
Replimune Group
REPL
$1.04B
$7.9M 0.47%
850,341
– –
2024 Q2
4 quarters
MTSR
28
DELISTED
Metsera Inc
MTSR
$7.72M 0.46%
271,529
+221,529
+443% +$5.5M
2025 Q1
1 quarter
ADAP
29
DELISTED
Adaptimmune Therapeutics
ADAP
$6.57M 0.39%
27,404,070
– –
2024 Q1
5 quarters
DAWN icon
30
DELISTED
Day One Biopharmaceuticals
DAWN
$5.6M 0.33%
862,068
– –
2024 Q3
3 quarters
HLVX icon
31
DELISTED
HilleVax
HLVX
$4.82M 0.29%
+2,420,243
New +$4.43M
2025 Q2
0 quarters
ATRA icon
32
Atara Biotherapeutics
ATRA
$95.5M
$4.42M 0.26%
573,183
– –
2023 Q4
6 quarters
WHWK icon
33
Whitehawk Therapeutics
WHWK
$169M
$2.04M 0.12%
1,091,417
-990,583
-48% -$1.72M
2024 Q3
3 quarters
MGNX icon
34
MacroGenics
MGNX
$208M
$1.94M 0.11%
+1,602,717
New +$2.32M
2025 Q2
0 quarters
QURE icon
35
CALL
uniQure
QURE
$1.52B
$1.88M 0.11%
135,000
– –
2024 Q4
2 quarters
NUVB.WS icon
36
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$1.88M 0.11%
963,333
– –
2021 Q1
17 quarters
SRZNW icon
37
DELISTED
Surrozen Inc Warrant
SRZNW
$596K 0.04%
66,665
– –
2021 Q2
16 quarters
ALGS icon
38
Aligos Therapeutics
ALGS
$31.6M
– –
-88,569
Closed -$731K –
BCYC icon
39
Bicycle Therapeutics
BCYC
$241M
– –
-910,000
Closed -$7.73M –
BEAM icon
40
Beam Therapeutics
BEAM
$2.4B
– –
-526,685
Closed -$10.3M –
DNA icon
41
Ginkgo Bioworks
DNA
$686M
– –
-1,462,328
Closed -$8.34M –
ETON icon
42
CALL
Eton Pharmaceutcials
ETON
$1.43B
– –
-50,500
Closed -$655K –
KROS icon
43
Keros Therapeutics
KROS
$213M
– –
-187,500
Closed -$1.91M –
PRME icon
44
Prime Medicine
PRME
$637M
– –
-700,000
Closed -$1.39M –
PRTA icon
45
Prothena Corp
PRTA
$431M
– –
-11,584,280
Closed -$143M –
RLAY icon
46
Relay Therapeutics
RLAY
$3.63B
– –
-641,426
Closed -$1.68M –
SLDB icon
47
Solid Biosciences
SLDB
$599M
– –
-744,450
Closed -$2.75M –
SRPT icon
48
Sarepta Therapeutics
SRPT
$1.81B
– –
-1,292,386
Closed -$82.5M –
TCRX icon
49
TScan Therapeutics
TCRX
$16.1M
– –
-662,833
Closed -$915K –
VERV icon
50
DELISTED
Verve Therapeutics
VERV
– –
-1,250,000
Closed -$5.71M –
1
2
3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2025 Portfolio in Review

As of Q2 2025, EcoR1 Capital held 52 positions worth $1.69B, up 0.2% from $1.69B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

EcoR1 Capital's Q2 2025 filing shows 6 new, 5 increased, 4 reduced and 15 closed positions. Its largest new stake was iTeos Therapeutics: 10,688,978 shares worth $107M. The largest sale was Prothena Corp, an estimated $143M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q2 2025 buy was iTeos Therapeutics: 10,688,978 shares worth $107M.
  • EcoR1 Capital added most to Zymeworks in Q2 2025, an estimated $68M increase.
  • EcoR1 Capital's biggest Q2 2025 reduction was Oric Pharmaceuticals, cutting an estimated $12.1M.
  • EcoR1 Capital fully exited Prothena Corp in Q2 2025, selling an estimated $143M.
  • EcoR1 Capital's ten largest holdings make up 77% of its $1.69B portfolio in Q2 2025.
  • EcoR1 Capital opened 6 new positions and closed 15 in Q2 2025.
  • EcoR1 Capital's portfolio value rose 0.2% quarter-over-quarter to $1.69B.

Based on EcoR1 Capital's 13F filing for Q2 2025, filed 14 Aug 2025.